Tampi Rajesh R, Manikkara Geetha, Balachandran Silpa, Taparia Piyush, Hrisko Stephanie, Srinivasan Shilpa, Tampi Deena J
Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Department of Psychiatry, MetroHealth, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.
Drugs Context. 2018 Feb 7;7:212517. doi: 10.7573/dic.212517. eCollection 2018.
The aim of this review was to identify published randomized control trials (RCTs) that evaluated the efficacy and tolerability of suvorexant for the treatment of insomnia among older adults (≥65 years). A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases for RCTs in any language evaluating suvorexant for the treatment of insomnia in older adults. Additionally, references of full-text articles that were included in this review were searched for further studies. Data from three RCTs of suvorexant were included in this review. All the three studies fulfilled the criteria for being of good quality based on the items listed by the Center for Evidence Based Medicine (CEBM) for the assessment of RCTs. None of the three studies were conducted exclusively among older adults. However, they also included older individuals diagnosed with primary insomnia. These studies included a total of 1298 participants aged ≥65 years in age. Trial durations ranged from 3 months to 1 year. Available data from these studies indicate that suvorexant improves multiple subjective and polysomnographic sleep parameters for sleep onset and maintenance among older individuals with a diagnosis of primary insomnia and is generally well tolerated. Current evidence, although limited, indicates that suvorexant benefits older adults with primary insomnia and is generally well tolerated.
本综述的目的是识别已发表的随机对照试验（RCT），这些试验评估了苏沃雷生治疗老年人（≥65岁）失眠的疗效和耐受性。我们在PubMed、MEDLINE、EMBASE、PsycINFO和Cochrane协作数据库中进行了文献检索，以查找任何语言的评估苏沃雷生治疗老年人失眠的RCT。此外，我们还检索了本综述中纳入的全文文章的参考文献，以寻找进一步的研究。本综述纳入了三项关于苏沃雷生的RCT数据。根据循证医学中心（CEBM）列出的评估RCT的项目，所有这三项研究均符合高质量标准。这三项研究均未仅在老年人中进行。然而，它们也纳入了被诊断为原发性失眠的老年人。这些研究总共纳入了1298名年龄≥65岁的参与者。试验持续时间从3个月到1年不等。这些研究的现有数据表明，苏沃雷生可改善诊断为原发性失眠的老年人入睡和维持睡眠的多个主观和多导睡眠图睡眠参数，并且总体耐受性良好。目前的证据虽然有限，但表明苏沃雷生对患有原发性失眠的老年人有益，并且总体耐受性良好。
